Market Cap | 2.82M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -4.4M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -28.00% |
Sales | 255.72k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -28.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -64.00% |
Recommedations | - | Quick Ratio | - | Shares Outstanding | 396.83M | 52W Low Chg | 900.00% |
Insider Own | 19.84% | ROA | -144.27% | Shares Float | 255.51M | Beta | -0.61 |
Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.01 |
Gross Margin | 96.21% | Profit Margin | - | Avg. Volume | 114,883 | Target Price | - |
Oper. Margin | -31,105.07% | Earnings Date | - | Volume | 61,040 | Change | -1.96% |
Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.